Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer

키워드

참고문헌 (25)

1. Cunningham D, "Colorectal cancer", Lancet, 375, pp.1030~1047 (2010)[DOI]
2. Tournigand C, "FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study", J Clin Oncol, 22, pp.229~237 (2004)[DOI]
3. Colucci G, "Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale", J Clin Oncol, 23, pp.4866~4875 (2005)[DOI]
4. Kirstein MM, "Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data", Oncologist, 19, pp.1156~1168 (2014)[DOI]
5. 김강미, "Usefulness of Carcinoembryonic Antigen for Monitoring Tumor Progression during Palliative Chemotherapy in Metastatic Colorectal Cancer", Yonsei Medical Journal, 54(1), pp.116~122 (2013), 연세대학교의과대학[DOI]
6. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)[DOI]
7. Huh JW, "Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer", J Surg Oncol, 101, pp.396~400 (2010)
8. Ward U, "The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer", Br J Cancer, 67, pp.1132~1135 (1993)[DOI]
9. Preketes AP, "CEA reduction after cryotherapy for liver metastases from colon cancer predicts survival", Aust N Z J Surg, 64, pp.612~614 (1994)[DOI]
10. Mekenkamp LJ, "Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases", Br J Cancer, 103, pp.159~164 (2010)[DOI]
11. Schwartz LH, "Evaluation of lymph nodes with RECIST 1.1", Eur J Cancer, 45, pp.261~267 (2009)[DOI]
12. Huang SC, "Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy", Ann Surg Oncol, 22, pp.2262~2268 (2015)[DOI]
13. Ruo L, "Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients", J Am Coll Surg, 196, pp.722~728 (2003)[DOI]
14. Meyerhardt JA, "Systemic therapy for colorectal cancer", N Engl J Med, 352, pp.476~487 (2005)[DOI]
15. Neki K, "Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer", Anticancer Res, 33, pp.1769~1772 (2013)
16. Zhao J, "Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer", Med Oncol, 31, pp.802~ (2014)[DOI]
17. Hu J, "Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma", Eur J Med Res, 20, pp.95~ (2015)[DOI]
18. Choi H, "Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria", J Clin Oncol, 25, pp.1753~1759 (2007)[DOI]
19. Adams RB, "Selection for hepatic resection of colorectal liver metastases: expert consensus statement", HPB (Oxford), 15, pp.91~103 (2013)[DOI]
20. Loupakis F, "Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab", Br J Cancer, 108, pp.2549~2556 (2013)[DOI]
21. Rubbia-Brandt L, "Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery", Ann Oncol, 18, pp.299~304 (2007)
22. Walker AS, "Future directions for monitoring treatment response in colorectal cancer", J Cancer, 5, pp.44~57 (2014)[DOI]
23. Cremolini C, "Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest", Ann Oncol, 26, pp.1188~1194 (2015)[DOI]
24. Piessevaux H, "Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab", J Clin Oncol, 31, pp.3764~3775 (2013)[DOI]
25. Michl M, "CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)", Ann Oncol, 27, pp.1565~1572 (2016)[DOI]

관련 논문AI추천